Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-anal Lopinavir/Ritonavir in PLWH With High-Grade Anal Intraepithelial Neoplasia
NCT05334004Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lopinavir + ritonavir in anal intraepithelial neoplasia (AIN) (6 cohorts), sponsored by University of Wisconsin–Madison. Primary endpoints: Maximum Tolerated Dose at 5 weeks and Rate of Grade 3 or above Toxicities in any Organ System at 5 weeks. Started Dec 2023; status: recruiting.
02
Drugs
lopinavir + ritonavir
03
Conditions
anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on NCT05334004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334004.